The Role of Hemoglobin and Anemia in Preventing Dementia—Revisiting a Well-Known Protein
-
By
-
Frank J. Wolters
-
April 17, 2026
Clinical Scorecard: The Role of Hemoglobin and Anemia in Preventing Dementia—Revisiting a Well-Known Protein
At a Glance
| Category | Detail |
|---|---|
| Condition | Dementia and its association with anemia |
| Key Mechanisms | Impaired oxygen transport to the brain, altered cerebral hemodynamics, iron and vitamin B metabolism disturbances, and Alzheimer pathology interaction |
| Target Population | Aging populations, especially those with anemia |
| Care Setting | Population-based and clinical settings focusing on aging and neurodegenerative disease prevention |
Key Highlights
- Anemia is associated with a 66% increased relative risk of developing dementia over approximately 9 years.
- A J-shaped relationship exists between hemoglobin levels and dementia risk, with increased risk below ~14 g/dL.
- Anemia interacts additively with plasma biomarkers of neurodegeneration (phosphorylated tau 217, neurofilament light chain, glial fibrillary acidic protein) to increase dementia risk 3- to 4-fold.
Guideline-Based Recommendations
Diagnosis
- Assess hemoglobin levels continuously to identify anemia and risk thresholds (~14 g/dL).
- Evaluate plasma biomarkers of neurodegeneration in patients with anemia for risk stratification.
Management
- Investigate and address underlying causes of anemia, including iron and vitamin B deficiencies.
- Consider interventions targeting oxygen delivery and cerebral hemodynamics to preserve neuronal health.
Monitoring & Follow-up
- Long-term follow-up of hemoglobin levels and cognitive status in at-risk populations.
- Monitor plasma biomarkers related to neurodegeneration in patients with anemia.
Risks
- Increased dementia risk with macrocytic and microcytic anemia compared to normocytic anemia.
- Potential confounding effects of chronic diseases and nutritional deficiencies on anemia-dementia association.
Patient & Prescribing Data
Older adults with anemia, particularly those with low hemoglobin levels and elevated neurodegenerative biomarkers
Addressing anemia and its causes may reduce dementia risk; however, mechanistic and interventional studies are needed to guide therapy.
Clinical Best Practices
- Screen aging patients for anemia and monitor hemoglobin levels regularly.
- Evaluate iron status and vitamin B levels to identify treatable causes of anemia.
- Incorporate biomarker assessments where available to better understand dementia risk.
- Consider sex differences and geographic diversity when applying prevention strategies.
- Promote research combining plasma and cerebrospinal fluid biomarkers with imaging and cognitive outcomes.
Related Resources & Content
- Valletta et al, SNAC-K study on anemia and dementia risk
- Niels Lassen seminal work on cerebral autoregulation
- Studies linking iron homeostasis and neurodegeneration
- Research on amyloid-β, iron, and Alzheimer disease
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
